Steven Cohen’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18.2M Buy
+630,283
New +$15.5M 0.02% 963
2026
Q2
– Sell
-1,021,808
Closed -$14.2M – 3936
2026
Q1
$14.2M Buy
1,021,808
+818,733
+403% +$13M 0.02% 1015
2025
Q4
$3.3M Sell
203,075
-116,396
-36% -$1.9M ﹤0.01% 2135
2025
Q3
$4.78M Sell
319,471
-1,054,452
-77% -$12.8M 0.01% 1089
2025
Q2
$16M Buy
+1,373,923
New +$12.5M 0.03% 576
2025
Q1
– Sell
-937,331
Closed -$5.62M – 1994
2024
Q4
$5.62M Buy
937,331
+441,839
+89% +$2.44M 0.01% 911
2024
Q3
$2.54M Buy
+495,492
New +$2.16M 0.01% 1097
2024
Q2
– Sell
-274,700
Closed -$882K – 1804
2024
Q1
$882K Sell
274,700
-3,447,800
-93% -$13.3M ﹤0.01% 1489
2023
Q4
$18.2M Sell
3,722,500
-1,990,800
-35% -$9.08M 0.04% 465
2023
Q3
$31.1M Buy
+5,713,300
New +$37.8M 0.09% 286
2019
Q3
– Sell
-50,000
Closed -$2.42M – 1096
2019
Q2
$2.42M Buy
+50,000
New +$2.22M 0.01% 631

Other funds holding ADPT

Steven Cohen's ADPT Position: Q3 2026 in Review

Steven Cohen opened a new position in Adaptive Biotechnologies (ADPT) in Q3 2026: 630,283 shares worth $18.2M. The stake represents 0.02% of the portfolio and ranks #963 among its holdings. This is a return to the name: Steven Cohen previously reported a position in ADPT as recently as Q1 2026.

Steven Cohen first reported a position in ADPT in Q2 2019 and has held it in 11 quarters since. The position peaked at $31.1M in Q3 2023. 331 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Steven Cohen held 630,283 shares of Adaptive Biotechnologies worth $18.2M as of Q3 2026.
  • Adaptive Biotechnologies was a new Steven Cohen position in Q3 2026.
  • Adaptive Biotechnologies made up 0.02% of Steven Cohen's portfolio in Q3 2026, its #963 holding.
  • Steven Cohen first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 11 quarters since.
  • Steven Cohen's Adaptive Biotechnologies position peaked at $31.1M in Q3 2023.
  • 331 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.